R.M. Sincerbeaux Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

R.M. Sincerbeaux Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-19,560	Closed	-$900K	–	55
2016 Q3	$900K	Hold	19,560	–	–	0.88%	32
2016 Q2	$982K	Hold	19,560	–	–	1.01%	31
2016 Q1	$1.05M	Hold	19,560	–	–	1.1%	29
2015 Q4	$1.28M	Hold	19,560	–	–	1.39%	27
2015 Q3	$1.1M	Hold	19,560	–	–	1.16%	29
2015 Q2	$1.16M	Sell	19,560 -1,356	-6%	-$83.6K	1.13%	28
2015 Q1	$1.3M	Sell	20,916 -11,300	-35%	-$657K	1.19%	26
2014 Q4	$1.85M	Buy	32,216 +356	+1%	+$19.8K	1.69%	24
2014 Q3	$1.71M	Sell	31,860 -356	-1%	-$18.9K	1.57%	26
2014 Q2	$1.69M	Hold	32,216	–	–	1.58%	26
2014 Q1	$1.7M	Hold	32,216	–	–	1.68%	22
2013 Q4	$1.29M	Buy	+32,216	New	+$1.27M	1.27%	28

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

R.M. Sincerbeaux Capital Management's TEVA Position: Q4 2016 in Review

R.M. Sincerbeaux Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 19,560 shares — an estimated $900K sold.

R.M. Sincerbeaux Capital Management first reported a position in TEVA in Q4 2013 and held it in 12 quarters. The position peaked at $1.85M in Q4 2014. 738 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

R.M. Sincerbeaux Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
R.M. Sincerbeaux Capital Management sold 19,560 Teva Pharmaceuticals shares in Q4 2016, an estimated $900K.
R.M. Sincerbeaux Capital Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 12 quarters.
R.M. Sincerbeaux Capital Management's Teva Pharmaceuticals position peaked at $1.85M in Q4 2014.
738 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on R.M. Sincerbeaux Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.